

Northwestern University Institutional Biosafety Committee

Meeting Minutes

Date: 8/20/2025 11:00 AM

Called to Order: 11:03 AM

Adjourned: 1:00 PM

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference (either Zoom or Microsoft Teams, as Northwestern policy requires). A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

IBC Members

Please see the NIH Office of Science Policy Registration Management System for official Committee Members' roles.

Name	Committee Role	Attendance
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	Present
Jacob Class	Member	Present
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	Present
Robert Foreman	Member	Present
Susan Fox	Member	Present
Lucy Godley	Member	-
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	Present
Sarah Kopp	Member	Present
Maciej Lesniak	Member	-
Stephen Levin	Member	Present
Liming Li	Member	Present
Emma Liechty	Member	-
Narsa Machireddy	Member	-
Michael McRaven	Member	Present
Jeremy T Ritzert	Member	Present
Irina Shepotinovskaya	Member	Present
Suchitra Swaminathan	Member	Present
Clyde Yancy	Member	-
Nicolette Zielinski-Mozny	Member	-
Robert Birkett	Alternate	-

Name	Committee Role	Attendance
Crista Brawley	Alternate	-
Jane Cullen	Alternate	-
Mandy Kozlowski	Alternate	-
Alicia McLuckie	Alternate	-
Marina Zelivyanskaya	Alternate	Present
James Zewe	Alternate	Present
Michael Hantak	Administrator	Present
Iwona Spath	Administrator	Present

Registrations for Full-Committee Review

Research Group	Principal Investigator	Submission Type
Adli Lab	Mazhar Adli	De Novo Review
Amato Lab	Katherine Amato	Initial Protocol
Brat Lab	Daniel Brat	De Novo Review
Caraveo Piso Lab	Gabriela Caraveo Piso	De Novo Review
Amendment for BIO20230009	Richard Green	Amendment
Hauser Lab	Alan Hauser	De Novo Review
He (Congcong) Lab	Congcong He	De Novo Review
Amendment for BIO20240118	Judd Hultquist	Amendment
Lavine Lab	Jeremy Lavine	Initial Protocol
Lee (Hojoon) Lab	Hojoon Lee	Initial Protocol
Leonard Lab	Joshua Leonard	De Novo Review
Li (Loretta) Lab	Loretta Li	De Novo Review
Temprian Oncology	SonBinh Nguyen	Initial Protocol
Amendment for BIO20220021	Samuel Stupp	Amendment
Tullman-Ercek Lab	Danielle Tullman-Ercek	Initial Protocol
Amendment for BIO20250073	Douglas Vaughan	Amendment
Amendment for BIO20220113	Adam Williams	Amendment
Wu (Jennifer) Lab	Jennifer Wu	Initial Protocol

Approval of Previous Meeting Minutes

Previous Meeting Date: 7/16/25

Determination: Approve

Comments: Smith made a motion to approve the meeting minutes. Hummel seconded the motion. The Committee unanimously supported the motion.

Meeting Minutes

Review of Adli Lab

De Novo Review

Principal Investigator: Mazhar Adli

Submission ID: BIO20250068

Applicable NIH Guidelines:

- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Brat Lab

De Novo Review

Principal Investigator: Daniel Brat

Submission ID: BIO20250085

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Caraveo Piso Lab

De Novo Review

Principal Investigator: Gabriela Caraveo Piso

Submission ID: BIO20250082

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3

Containment Level: BSL-2

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Amendment for BIO20230009

Amendment

Principal Investigator: Richard Green

Submission ID: BIO20230009-AM0004

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Hauser Lab

De Novo Review

Principal Investigator: Alan Hauser

Submission ID: BIO20250089

Applicable NIH Guidelines:

- Section III-F-2
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-F-8-C-VIII
- Section III-F-8
- Section III-F-6

Containment Level: BSL-2

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of He (Congcong) Lab

De Novo Review

Principal Investigator: Congcong He

Submission ID: BIO20250093

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20240118

Amendment

Principal Investigator: Judd Hultquist

Submission ID: BIO20240118-AM0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-F-3
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-D-3-a

Containment Level: BSL-2+

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Lavine Lab

Initial Protocol

Principal Investigator: Jeremy Lavine

Submission ID: BIO20250071

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-D-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Lee (Hojoon) Lab

Initial Protocol

Principal Investigator: Hojoon Lee

Submission ID: BIO20250032

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Leonard Lab

De Novo Review

Principal Investigator: Joshua Leonard

Submission ID: BIO20250077

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-F-2
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-3

Containment Level: BSL-2

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Li (Loretta) Lab

De Novo Review

Principal Investigator: Loretta Li

Submission ID: BIO20250087

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2+

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Temprian Oncology

Initial Protocol

Principal Investigator: SonBinh Nguyen

Submission ID: BIO20240049

Applicable NIH Guidelines:

- Section III-F
- Section III-E
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20220021

Amendment

Principal Investigator: Samuel Stupp

Submission ID: BIO20220021-AM0001

Applicable NIH Guidelines:

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Associated IACUC Studies: N/A

Associated IRB Studies: N/A

Supporting Documents: None

Review of Tullman-Ercek Lab

Initial Protocol

Principal Investigator: Danielle Tullman-Ercek

Submission ID: BIO20240081

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E
- Section III-D-1
- Section III-D-2
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20250073

Amendment

Principal Investigator: Douglas Vaughan

Submission ID: BIO20250073-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-F-8-C-VIII

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20220113

Amendment

Principal Investigator: Adam Williams

Submission ID: BIO20220113-AM0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-7
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Wu (Jennifer) Lab

Initial Protocol

Principal Investigator: Jennifer Wu

Submission ID: BIO20250022

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve with modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Administratively-Approved Exempt Registrations and Amendments

Continuing Review for BIO20220041

Continuing Review

Principal Investigator: Guillermo Ameer

Submission ID: BIO20220041-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-b
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/7/25

Arango Lab

Initial Protocol

Principal Investigator: Daniel Arango

Submission ID: BIO20250026

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/18/25

Amendment/CR for BIO20220140

Amendment/CR

Principal Investigator: Ankit Bharat

Submission ID: BIO20220140-AMCR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-7
- Section III-E-3-a
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/30/25

Continuing Review for BIO20220086

Continuing Review

Principal Investigator: Shi-Yuan Cheng

Submission ID: BIO20220086-CR0001

Applicable NIH Guidelines:

- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/16/25

Continuing Review for BIO20240107

Continuing Review

Principal Investigator: Insup Choi

Submission ID: BIO20240107-CR0001

Applicable NIH Guidelines:

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/18/25

Continuing Review for BIO20240124

Continuing Review

Principal Investigator: Julius P Dewald

Submission ID: BIO20240124-CR0001

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 8/4/25

Continuing Review for BIO20220101

Continuing Review

Principal Investigator: Hongxin Dong

Submission ID: BIO20220101-CR0002

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/15/25

Continuing Review for BIO20230060

Continuing Review

Principal Investigator: Igor Efimov

Submission ID: BIO20230060-CR0002

Applicable NIH Guidelines:

- Section III-F
- Section III-E
- Section III-F-8-C-VII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/18/25

Continuing Review for BIO20230094

Continuing Review

Principal Investigator: Cara Gottardi

Submission ID: BIO20230094-CR0003

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-D-4-b
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/1/25

Continuing Review for BIO20220072

Continuing Review

Principal Investigator: Yogesh Goyal

Submission ID: BIO20220072-CR0002

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3

Containment Level: BSL-2

Approval Date: 8/1/25

Continuing Review for BIO20220137

Continuing Review

Principal Investigator: Mitra Hartmann

Submission ID: BIO20220137-CR0001

Applicable NIH Guidelines:

- Section III-D-1
- Section III-D

Containment Level: BSL-2

Approval Date: 7/29/25

Continuing Review for BIO20240062

Continuing Review

Principal Investigator: Wellington Hsu

Submission ID: BIO20240062-CR0001

Applicable NIH Guidelines:

- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/14/25

Continuing Review for BIO20240101

Continuing Review

Principal Investigator: Mike Jewett

Submission ID: BIO20240101-CR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-4
- Section III-F-8

Containment Level: BSL-1

Approval Date: 7/21/25

Continuing Review for BIO20220143

Continuing Review

Principal Investigator: Bin Jiang

Submission ID: BIO20220143-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-8-C-VII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/24/25

Amendment/CR for BIO20220097

Amendment/CR

Principal Investigator: Seema Khan

Submission ID: BIO20220097-AMCR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/14/25

Continuing Review for BIO20240117

Continuing Review

Principal Investigator: Valerie Kilman

Submission ID: BIO20240117-CR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-D

Containment Level: BSL-1

Approval Date: 8/13/25

Continuing Review for BIO20220104

Continuing Review

Principal Investigator: Eyal Kimchi

Submission ID: BIO20220104-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-b
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/1/25

Amendment for BIO20240008

Amendment

Principal Investigator: Fei Li Kuang

Submission ID: BIO20240008-AM0001

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/31/25

Continuing Review for BIO20240078

Continuing Review

Principal Investigator: Laura Lackner

Submission ID: BIO20240078-CR0001

Applicable NIH Guidelines:

- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8-C-III
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/19/25

Continuing Review for BIO20240090

Continuing Review

Principal Investigator: Richard Lieber

Submission ID: BIO20240090-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/4/25

Stanley Manne Flow Cytometry Facility

Initial Protocol

Principal Investigator: Elizabeth Managlia

Submission ID: BIO20250097

Applicable NIH Guidelines:

- Section III-F
- Section III-F-8

Containment Level: BSL-1

Approval Date: 8/13/25

Continuing Review for BIO20220055

Continuing Review

Principal Investigator: Herbert Meltzer

Submission ID: BIO20220055-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-D

Containment Level: BSL-1

Approval Date: 1/27/25

Amendment for BIO20220015

Amendment

Principal Investigator: Stephen Miller

Submission ID: BIO20220015-AM0002

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/18/25

Continuing Review for BIO20220015

Continuing Review

Principal Investigator: Stephen Miller

Submission ID: BIO20220015-CR0002

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/11/25

Continuing Review for BIO20220071

Continuing Review

Principal Investigator: Booki Min

Submission ID: BIO20220071-CR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/25/25

Continuing Review for BIO20240043

Continuing Review

Principal Investigator: Luisa Morales-Nebreda

Submission ID: BIO20240043-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-7
- Section III-D-4
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 7/21/25

Amendment for BIO20240130

Amendment

Principal Investigator: Brian Mustanski

Submission ID: BIO20240130-AM0001

Applicable NIH Guidelines:

- Section III-F-1

Containment Level: BSL-2

Approval Date: 8/11/25

Amendment for BIO20230057

Amendment

Principal Investigator: Han Peng

Submission ID: BIO20230057-AM0002

Applicable NIH Guidelines:

- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/11/25

Continuing Review for BIO20230028

Continuing Review

Principal Investigator: Seth Pollack

Submission ID: BIO20230028-CR0002

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/28/25

Amendment/CR for BIO202300628

Amendment/CR

Principal Investigator: Jonathan Rivnay

Submission ID: BIO20230062-AMCR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 4/7/25

Continuing Review for BIO20220009

Continuing Review

Principal Investigator: Paul Schumacker

Submission ID: BIO20220009-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/30/25

Continuing Review for BIO20230068

Continuing Review

Principal Investigator: Rocio Servin-Vences

Submission ID: BIO20230068-CR0002

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 8/18/25

Amendment for BIO20240195

Amendment

Principal Investigator: Arun Sharma

Submission ID: BIO20240195-AM0002

Applicable NIH Guidelines:

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/15/25

Continuing Review for BIO20220001

Continuing Review

Principal Investigator: Greg Smith

Submission ID: BIO20220001-CR0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-F-2
- Section III-D-4
- Section III-F
- Section III-D-2-a
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/21/25

Continuing Review for BIO20220060

Continuing Review

Principal Investigator: Ronen Sumagin

Submission ID: BIO20220060-CR0001

Applicable NIH Guidelines:

- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/24/25

Continuing Review for BIO20230024

Continuing Review

Principal Investigator: Dalton Surmeier Jr

Submission ID: BIO20230024-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/18/25

Amendment for BIO20230115

Amendment

Principal Investigator: Bowen Wang

Submission ID: BIO20230115-AM0002

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-E-3
- Section III-D-4-b
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/28/25

Amendment for BIO20230115

Amendment

Principal Investigator: Bowen Wang

Submission ID: BIO20230115-AM0003

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-E-3
- Section III-D-4-b
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/19/25

Continuing Review for BIO20240080

Continuing Review

Principal Investigator: Joshua Wechsler

Submission ID: BIO20240080-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/18/25

Continuing Review for BIO20230100

Continuing Review

Principal Investigator: Sam Weinberg

Submission ID: BIO20230100-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 7/21/25

Continuing Review for BIO20230035

Continuing Review

Principal Investigator: Donna Whitlon

Submission ID: BIO20230035-CR0001

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 7/14/25

Amendment for BIO20220144

Amendment

Principal Investigator: David Williams

Submission ID: BIO20220144-AM0002

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 8/19/25

Continuing Review for BIO20230109

Continuing Review

Principal Investigator: Steven Wolinsky

Submission ID: BIO20230109-CR0003

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-D-3

Containment Level: BSL-2+

Approval Date: 8/11/25

Continuing Review for BIO20240136

Continuing Review

Principal Investigator: Catherine Woolley

Submission ID: BIO20240136-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/4/25

Continuing Review for BIO20240103

Continuing Review

Principal Investigator: Yang Yi

Submission ID: BIO20240103-CR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 7/24/25

Continuing Review for BIO20230044

Continuing Review

Principal Investigator: Feng Yue

Submission ID: BIO20230044-CR0002

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 7/14/25

Continuing Review for BIO20240030

Continuing Review

Principal Investigator: Christine Zhang

Submission ID: BIO20240030-CR0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-D-2-a
- Section III-F-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 8/4/25

Amendment for BIO20240038

Amendment

Principal Investigator: Youyang Zhao

Submission ID: BIO20240038-AM0002

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 7/24/25

Continuing Review for BIO20240038

Continuing Review

Principal Investigator: Youyang Zhao

Submission ID: BIO20240038-CR0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 7/14/25

Other Agenda Items

Description: IBC Self-Assessment Review 2025

Related Projects:

Notes: The IBC Self-Assessment document is available in the documents tab of the meeting page. This document was completed by the IBC Team and reviewed by IBC Member volunteers.

Description: Review Timeliness

Related Projects:

Notes: Please remember to complete reviews within the requested time frame. PIs are your colleagues and their work cannot proceed until the IBC completes its obligations. If you are not able to complete your review in the requested time frame, please contact IBC staff. Thank you!

Description: NIH Response to Incident Report

Related Projects:

Notes: The NIH responded to our incident report and stated that no further action is necessary. See attached document.

Description: Ongoing Resolution of Non-Compliance Determination

Related Projects: BIO20240038

Notes: The Zhao (Youyang) Lab has complied with the IBC determination following recent non-compliance determination.